72 related articles for article (PubMed ID: 25844935)
21. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698
[TBL] [Abstract][Full Text] [Related]
24. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
Tseden-Ish M; Choi YD; Cho HJ; Ban HJ; Oh IJ; Kim KS; Song SY; Na KJ; Ahn SJ; Choi S; Kim YC
Respirology; 2012 Jan; 17(1):127-33. PubMed ID: 21899657
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer.
Gu J; Ding JY; Lu CL; Lin ZW; Chu YW; Zhao GY; Guo J; Ge D
Lung Cancer; 2013 Aug; 81(2):259-65. PubMed ID: 23706417
[TBL] [Abstract][Full Text] [Related]
26. Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer.
Wu YH; Cheng YW; Chang JT; Wu TC; Chen CY; Lee H
Cancer; 2007 Jul; 110(1):215-23. PubMed ID: 17508409
[TBL] [Abstract][Full Text] [Related]
27. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
28. Methylation of AKAP12{alpha} promoter in lung cancer.
Jo UH; Whang YM; Sung JS; Kim YH
Anticancer Res; 2010 Nov; 30(11):4595-600. PubMed ID: 21115911
[TBL] [Abstract][Full Text] [Related]
29. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of FBP1 by ZEB1-mediated repression confers to growth and invasion in lung cancer cells.
Zhang J; Wang J; Xing H; Li Q; Zhao Q; Li J
Mol Cell Biochem; 2016 Jan; 411(1-2):331-40. PubMed ID: 26546081
[TBL] [Abstract][Full Text] [Related]
31. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
[TBL] [Abstract][Full Text] [Related]
32. Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance.
Tomiyasu M; Yoshino I; Suemitsu R; Okamoto T; Sugimachi K
Clin Cancer Res; 2002 Dec; 8(12):3755-60. PubMed ID: 12473586
[TBL] [Abstract][Full Text] [Related]
33. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
34. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
35. [Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer].
Ma W; Li W; Gao M; Li XN
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):371-4. PubMed ID: 21875468
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
[TBL] [Abstract][Full Text] [Related]
37. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery.
Dai CH; Li J; Shi SB; Yu LC; Ge LP; Chen P
Jpn J Clin Oncol; 2010 Apr; 40(4):327-35. PubMed ID: 20056675
[TBL] [Abstract][Full Text] [Related]
38. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer.
Liu L; Zhao E; Li C; Huang L; Xiao L; Cheng L; Huang X; Song Y; Xu D
Cancer Epidemiol; 2013 Feb; 37(1):71-8. PubMed ID: 22959342
[TBL] [Abstract][Full Text] [Related]
39. Elevated activities of MMP-2 in the non-tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival.
Kim SH; Choi HY; Lee J; Son DS; Lee HS; Song IS; Lim YS; Hong YS; Kim J; Choi YS
J Surg Oncol; 2007 Mar; 95(4):337-46. PubMed ID: 17326127
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]